Alnylam proposes $675M follow-on

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) proposed on Monday to raise $675 million in a follow-on underwritten by Goldman Sachs, JPMorgan, Barclays and Credit Suisse.

Also on Monday, Alnylam said EMA granted accelerated assessment to patisiran (ALN-TTR02) to treat familial amyloidotic polyneuropathy (FAP), a form of transthyretin (TTR) amyloidosis.This month, Alnylam and the Sanofi Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) reported detailed data from the Phase III APOLLO trial to treat FAP in which patisiran met the primary endpoint (see BioCentury Extra, Nov. 2)...